menu

Reconsidering the Algorithm: DME

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Reducing Retina Treatment Burden in the Real World: Emerging Evidence with Treatment Advances

Reconsidering the Algorithm: DME

MinuteCE®
ReachMD Healthcare Image
Restart
Resume
Choose a format
Media formats available:
Take 1 Minute Challenge
1 Minute Challenge Completed
1.00 credits
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Details
Episodes
Presenters
Related
Comments
  • Overview

    The approval of new, more durable treatments is an exciting development for the management of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME), but how do these therapies and their unique mechanisms stack up outside of clinical trials? Join Dr. Durga Borkar, Dr. Sabin Dang, Dr. Jayanth Sridhar, and Dr. Christina Weng as they discuss these new treatments and the emerging data surrounding their use in the real world.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Faculty:

    Durga Borkar, MD, MMCi
    Assistant Professor of Ophthalmology
    Duke University Eye Center
    Durham, NC

    Consulting Fees: AbbVie/Allergan, Genentech, Glaukos, Iveric Bio, Verana Health

    Christina Y. Weng, MD, MBA
    Professor of Ophthalmology
    Program Director, Vitreoretinal Diseases & Surgery Fellowship Program
    Baylor College of Medicine
    Houston, TX

    Consulting Fees: AbbVie/Allergan, Alcon, Alimera Sciences, DORC, EyePoint, Genentech, Iveric Bio, Novartis, Regeneron, REGENXBIO
    Royalties: Springer Publishers
    Research: AGTC, Alimera Sciences, DRCR Retina Network

    Jayanth Sridhar, MD
    Chief of Ophthalmology, Vitreoretinal Surgeon
    Olive View Medical Center
    University of California, Los Angeles
    Los Angeles, CA

    Consulting Fees: Genentech, Regeneron

    Sabin Dang, MD
    Vitreoretinal Surgeon
    The Retina Institute
    St. Louis, MO

    Consulting Fees: Bausch and Lomb, Genentech, Regeneron
    Research: Bausch and Lomb, Genentech

    Reviewers/Content Planners/Authors:

    • Stephan Chavez has nothing to disclose.
    • Cindy Davidson has nothing to disclose.
    • Ann Early has nothing to disclose.
    • Andrea Mathis has nothing to disclose.
    • Brian P. McDonough, MD, FAAFP, has nothing to disclose.
    • Tim Person has nothing to disclose.
    • Stephanie Wenick, MPhil, has nothing to disclose.
  • Learning Objectives

     After participating in this educational activity, participants should be better able to:

    • Explore recent clinical evidence for the treatment of retinal diseases
    • Examine real-world evidence for the treatment of retinal diseases
    • Evaluate costs associated with durable treatments of retinal diseases
    • Integrate cost-effective, durable treatments for the management of retinal diseases
  • Target Audience

    This activity is designed to meet the educational needs of ophthalmologists and optometrists.

  • Accreditation and Credit Designation Statements

    In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

     

    Global Learning Collaborative is accredited by COPE to provide continuing education to optometrists.

    Global Learning Collaborative (GLC) designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for 1.0 nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

    This course is to be approved for 1.0 CE credit. Course ID is 87276-TD. Check with your local state licensing board to see if this counts toward your CE requirement for relicensure.

  • Provider(s)/Educational Partner(s)

    Prova Education designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties. 

    Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the very best education in the most impactful manner and to verify its results with progressive outcomes research. 

  • Commercial Support

    This activity is supported by an independent educational grant from Genentech, a member of the Roche Group.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    • Supported Browsers (2 most recent versions):
      • Google Chrome for Windows, Mac OS, iOS, and Android
      • Apple Safari for Mac OS and iOS
      • Mozilla Firefox for Windows, Mac OS, iOS, and Android
      • Microsoft Edge for Windows
    • Recommended Internet Speed: 5Mbps+

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Schedule22 May 2024